As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.

Officers, beneficial owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks ...

Story Feb. 13 - Moderna: The big biotech is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees. The IT workforce reductions come as ...

Moderna Inc., a biotechnology and pharmaceutical company reorienting its business for a post-pandemic age, awarded almost $17 ...

Moderna (NasdaqGS:MRNA) saw an 11% increase in share price over the last week, likely influenced by recent legal and financial developments. The announcement of multiple international lawsuits from ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Citi initiated coverage of Moderna (MRNA) with a Neutral rating and $40 price target Healthcare policy remains a key biopharma sector ...

Arcturus Therapeutics believes it’s “highly unlikely” it will lose the promised government funding for its bird flu mRNA ...

Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever received at the company. | While Stéphane Bancel received a ...